![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0036.png)
36
TNFSF11 (RANKL) and IL-6 polymorphisms.
Mol Genet Metab 2011;103:287-92.
29.
Chung PY, Beyens G, Boonen S, Papapoulos S,
Geusens P, Karperien M, et al. The majority of
the genetic risk for Paget's disease of bone is
explained by genetic variants close to the CSF1,
OPTN, TM7SF4, and TNFRSF11A genes. Hum
Genet 2010;128:615-26.
30.
Cundy T, Reid IR. Paget's disease of bone. Clin
Biochem. 2012;45:43-8.
31.
Chung PY, Van Hul W. Paget's Disease of Bone:
Evidence
for
Complex
Pathogenetic
Interactions.
Semin
Arthritis
Rheum
2012;41:619-41.
32.
Whyte MP. Clinical practice. Paget`s disease of
bone. N Engl J Med 2006; 355:593-600.
33.
Wermers RA, Tiegs RD, Atkinson EJ,
Achenbach SJ, Melton LJ 3rd. Morbidity and
mortality associated with Paget´s disease of
bone: a population-based study. J Bone Miner
Res 2008;23:819-25.
34.
Seton M, Moses AM, Bode RK, Schwartz C.
Paget`s disease of bone: the skeletal distribution,
complications and quality of life as perceived by
patients. Bone 2011;48:281-5.
35.
Hosking D, Meunier PJ, Ringe JD, Reginster
JY,Gennari C. Paget´s disease of bone: diagnosis
and management.BMJ 1996; 312:491-4